Formulations for AAV gene therapy
Formulations with sugars, buffers, and surfactants stabilize AAV particles across varying temperatures, addressing stability issues and enabling alternative storage options.
JP2025533988APending Publication Date: 2025-10-09MEIRAGTX UK LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025521086
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-11
- Filing Date
- 2023-10-11
- Publication Date
- 2025-10-09
AI Technical Summary
Technical Problem
AAV gene therapies are not stable at refrigeration temperatures and freezing processes compromise product quality, limiting delivery options and increasing costs.
Method used
Formulations comprising sugars, buffers, salts, and surfactants, such as trehalose, polysorbate 80, and sodium chloride, maintain AAV viability and infectivity across various temperatures, including ambient to -80°C, and withstand multiple freeze/thaw cycles.
Benefits of technology
Stabilizes AAV particles over extended periods and multiple freeze/thaw cycles, reducing reliance on cold chains and enhancing product accessibility and manufacturability.
✦ Generated by Eureka AI based on patent content.
Abstract
A composition for preserving and maintaining viral viability, comprising a balance of ionic strength and osmolality, that results in reproducible and stable product quality at room temperature, 4°C, and has the ability to withstand 10 freeze / thaw events.
Need to check novelty before this filing date? Find Prior Art